Relay Therapeutics is trading 4.3% up now at $20.62 after several analysts, including Citizens JMP and Goldman Sachs, raised their price targets and reaffirmed "Buy" ratings today.
These upgrades followed the company's August 6 earnings update, which cited a strategic shift toward front-line breast cancer and extended cash runway through 2029.
Initial positive vascular-anomalies data and expansion cohorts further supported pipeline enthusiasm, while ATM capacity was expanded to approximately $463 million on August 6.